naftopidil has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arima, K; Ishii, K; Iwamoto, Y; Kajiwara, S; Kanda, H; Kato, M; Miki, M; Shiraishi, T; Sugimura, Y | 1 |
| Hasegawa, Y; Masue, N | 1 |
2 other study(ies) available for naftopidil and Adenocarcinoma
| Article | Year |
|---|---|
Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Chemoradiotherapy; Combined Modality Therapy; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthalenes; Piperazines; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2017 |
[Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Drug Administration Schedule; Drug Therapy, Combination; Goserelin; Humans; Magnetic Resonance Imaging; Male; Naphthalenes; Nitriles; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2007 |